Longitudinal Retinal Changes in MOGAD.
Case-Control Studies
Cohort Studies
Humans
Immunologic Deficiency Syndromes
/ complications
Longitudinal Studies
Myelin-Oligodendrocyte Glycoprotein
/ immunology
Optic Neuritis
/ complications
Retina
/ diagnostic imaging
Retinal Degeneration
/ etiology
Retinal Neurons
Tomography, Optical Coherence
/ methods
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
09
06
2022
received:
24
08
2021
accepted:
10
06
2022
pubmed:
16
6
2022
medline:
23
8
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Patients with myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro-axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON-independent retinal atrophy can be detected in MOGAD. Eighty patients with MOGAD and 139 healthy controls (HCs) were included. OCT data was acquired with (1) Spectralis spectral domain OCT (MOGAD: N = 66 and HCs: N = 103) and (2) Cirrus high-definition OCT (MOGAD: N = 14 and HCs: N = 36). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) were quantified. At baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD-ON) compared with MOGAD eyes without a history of ON (MOGAD-NON) and HCs (p < 0.001). MOGAD-NON eyes had lower GCIPL volume compared to HCs (p < 0.001) in the Spectralis, but not in the Cirrus cohort. Longitudinally (follow-up up to 3 years), MOGAD-ON with ON within the last 6-12 months before baseline exhibited greater pRNFL thinning than MOGAD-ON with an ON greater than 12 months ago (p < 0.001). The overall MOGAD cohort did not exhibit faster GCIPL thinning compared with the HC cohort. Our study suggests the absence of attack-independent retinal damage in patients with MOGAD. Yet, ongoing neuroaxonal damage or edema resolution seems to occur for up to 12 months after ON, which is longer than what has been reported with other ON forms. These findings support that the pathomechanisms underlying optic nerve involvement and the evolution of OCT retinal changes after ON is distinct in patients with MOGAD. ANN NEUROL 2022;92:476-485.
Substances chimiques
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-485Investigateurs
Ayse Altintas
(A)
Fereshte Ashtari
(F)
Denis Bichuetti
(D)
Ibis Soto de Castillo
(IS)
Mariana Andrade
(M)
None Fontenelle
Saif Huda
(S)
Jae-Won Hyun
(JW)
Anu Jacob
(A)
Rahele Kafieh
(R)
Ho Jin Kim
(HJ)
Letizia Leocani
(L)
Yang Mao-Draayer
(Y)
Marie Isabel Leite
(MI)
Eugene F May
(EF)
Jaqueline Palace
(J)
Marco Aurélio Lana Peixoto
(MA)
Marco Pisa
(M)
Marta Radaelli
(M)
Zoe Rimler
(Z)
Adriana Roca-Fernandez
(A)
Thomas Senger
(T)
Jérôme de Seze
(J)
Sasitorn Siritho
(S)
Hadas Stiebel-Kalish
(H)
Uygur Tanriverdi
(U)
Ivan Maynart Tavares
(IM)
Caryl Tongco
(C)
Informations de copyright
© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Schmidt F, Zimmermann H, Mikolajczak J, et al. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2017;11:45-50.
Oertel FC, Outteryck O, Knier B, et al. Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. J Neuroinflammation 2019;16:154.
Filippatou AG, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis. Front Neurol 2020;11:540156.
Sotirchos ES, Filippatou A, Fitzgerald KC, et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler 2019;1352458519864928:1360-1371.
Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015;2:295-301.
Jarius S, Metz I, König FB, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in “pattern II multiple sclerosis” and brain biopsy findings in a MOG-IgG-positive case. Mult Scler 2016;22:1541-1549.
Höftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 2020;139:875-892.
Takai Y, Misu T, Kaneko K, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 2020;143:1431-1446.
Pache F, Zimmermann H, Mikolajczak J, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016;13:282.
Havla J, Kümpfel T, Schinner R, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol 2017;264:139-151.
Syc SB, Saidha S, Newsome SD, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2012;135:521-533.
Andorrà M, Alba-Arbalat S, Camos-Carreras A, et al. Using acute optic neuritis trials to assess neuroprotective and Remyelinating therapies in multiple sclerosis. JAMA Neurol 2020;77:234-244.
Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2017;16:797-812.
Sotirchos ES, Gonzalez Caldito N, Filippatou A, et al. Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy. Ann Neurol 2020;87:885-896.
Specovius S, Zimmermann HG, Oertel FC, et al. Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open 2020;10:e035397.
Oertel FC, Specovius S, Zimmermann HG, et al. Retinal optical coherence tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm 2021;8:e1068. Available at: https://nn.neurology.org/content/8/6/e1068. Accessed September 15, 2021.
Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15:134.
Nolan RC, Galetta SL, Frohman TC, et al. Optimal Intereye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in multiple sclerosis. J Neuroophthalmol 2018;38:451-458.
Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020;7:e674.
Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE 2012;7:e34823.
Schippling S, Balk LJ, Costello F, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler 2015;21:163-170.
R Development Core Team. R: a language and environment for statistical computing [internet]. Vienna, Austria: R Foundation for Statistical Computing, 2008 Available at: http://www.R-project.org.
Chen JJ, Sotirchos ES, Henderson AD, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and multiple sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Multiple Sclerosis and Related Disorders 2022;58:103525. Available at: https://www.msard-journal.com/article/S2211-0348(22)00040-2/fulltext. Accessed January 13, 2022.
Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-481.
Akaishi T, Nakashima I, Takeshita T, et al. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol 2016;299:152-157.
Oertel FC, Havla J, Roca-Fernández A, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry 2018;89:1259-1265.
Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 2016;22:470-482.
Costello F, Pan YI, Yeh EA, et al. The temporal evolution of structural and functional measures after acute optic neuritis. J Neurol Neurosurg Psychiatry 2015;86:1369-1373.
Henderson APD, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010;133:2592-2602.
Felix CM, Levin MH, Verkman AS. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflamm 2016;13:275.
Filippatou AG, Vasileiou ES, He Y, et al. Optic neuritis-independent retinal atrophy in Neuromyelitis Optica Spectrum disorder. J Neuroophthalmol 2021;42:e40-e47.
Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 2013;80:1406-1414.
Motamedi S, Oertel FC, Yadav SK, et al. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2020;7:e805.
Balk LJ, Cruz-Herranz A, Albrecht P, et al. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol 2016;263:1323-1331.
Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021;20:762-772.